Capricor Therapeutics (NASDAQ:CAPR) Shares Gap Up – Here’s What Happened

Shares of Capricor Therapeutics Inc (NASDAQ:CAPR) gapped up before the market opened on Tuesday . The stock had previously closed at $13.67, but opened at $15.11. Capricor Therapeutics shares last traded at $15.05, with a volume of 1,851,624 shares changing hands.

Wall Street Analysts Forecast Growth

Several research analysts recently weighed in on CAPR shares. HC Wainwright reiterated a “buy” rating and issued a $77.00 price objective on shares of Capricor Therapeutics in a research report on Tuesday. Cantor Fitzgerald raised their price target on shares of Capricor Therapeutics from $25.00 to $30.00 and gave the company an “overweight” rating in a research report on Thursday, November 14th. One equities research analyst has rated the stock with a sell rating and six have given a buy rating to the company’s stock. Based on data from MarketBeat, Capricor Therapeutics presently has an average rating of “Moderate Buy” and an average price target of $34.50.

Capricor Therapeutics Price Performance

The company has a market capitalization of $633.35 million, a price-to-earnings ratio of -13.26 and a beta of 4.08. The stock has a 50 day simple moving average of $14.41 and a two-hundred day simple moving average of $13.87.

Institutional Investors Weigh In On Capricor Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in CAPR. Oppenheimer & Co. Inc. boosted its holdings in Capricor Therapeutics by 25.2% in the third quarter. Oppenheimer & Co. Inc. now owns 68,408 shares of the biotechnology company’s stock valued at $1,040,000 after purchasing an additional 13,762 shares in the last quarter. The Manufacturers Life Insurance Company purchased a new stake in shares of Capricor Therapeutics during the 3rd quarter worth approximately $161,000. FMR LLC acquired a new position in shares of Capricor Therapeutics in the 3rd quarter valued at $370,000. BNP Paribas Financial Markets raised its stake in Capricor Therapeutics by 868.7% during the 3rd quarter. BNP Paribas Financial Markets now owns 17,699 shares of the biotechnology company’s stock worth $269,000 after acquiring an additional 15,872 shares in the last quarter. Finally, Fred Alger Management LLC purchased a new stake in Capricor Therapeutics in the third quarter valued at $399,000. Institutional investors and hedge funds own 21.68% of the company’s stock.

Capricor Therapeutics Company Profile

Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.